Results 241 to 250 of about 69,918 (298)

Myocardial perfusion and ACE inhibition.

Reviews in cardiovascular medicine, 2003
openaire   +1 more source

Clinical Pharmacology of ACE Inhibition

Cardiology, 2008
The radioimmunological determinations of immunoreactive ‘angiotensin IF do not truly reflect angiotensin-(l-8)octapeptide levels, and thus cannot provide an accurate reflection of the efficacy of angiotensin-converting enzyme (ACE) inhibition. Elaborate methods are necessary to measure specifically the octapeptide angiotensin II.
Nussberger J, Waeber B, Brunner HR
openaire   +4 more sources

Differential Inhibition of Plasma Versus Tissue ACE by Utibapril: Biochemical and Functional Evidence for Inhibition of Vascular ACE Activity

Journal of Cardiovascular Pharmacology, 1997
Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with a proposed tissue-specific inhibitory profile. This implies that at a certain dose, utibapril should be able to inhibit tissue ACE activity without affecting plasma ACE. Moreover, if tissue ACE activity is rate limiting, functional conversion of angiotensin I should be decreased ...
Buikema, H., Pinto, Y. M., van Geel, P. P., Rooks, G., de Langen, C. D., de Graeff, P. A., van Gilst, W. H.   +6 more
openaire   +4 more sources

Evaluating the association between genetically proxied ACE inhibition and dementias

Alzheimer's and Dementia, 2023
Introduction: Angiotensin-converting enzyme (ACE) has been implicated in the metabolism of amyloid beta; however, the causal effect of ACE inhibition on risk of Alzheimer's disease (AD) dementia and other common dementias is largely unknown.
Malik Nassan, Iyas Daghlas, Emily Rogalski   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

ACE inhibition and atherogenesis

Canadian Journal of Physiology and Pharmacology, 2002
Recent clinical studies such as HOPE, SECURE, and APRES show that angiotensin-converting enzyme (ACE) inhibitors like ramipril improve the prognosis of patients with a high risk of atherothrombotic cardiovascular events. Atherosclerosis, as a chronic inflammatory condition of the vascular system, can turn into an acute clinical event through the ...
B A, Schölkens, W, Landgraf
openaire   +3 more sources

Cardiac Effects of ACE Inhibition

Journal of Cardiovascular Pharmacology, 1993
Hypertension frequently is associated with a number of changes in heart structure and function, such as left ventricular hypertrophy, disturbed diastolic function, and subnormal stroke volume during exercise. Most of these changes probably are related to myocardial fibrosis.
P, Lund-Johansen, P, Omvik
openaire   +2 more sources

ACE Inhibition

Circulation, 1997
Background The mechanisms by which ACE inhibitors produce a sustained clinical benefit are not entirely clear but may involve the sympathetic nervous system. We compared the effect of local brachial artery infusions of an ACE inhibitor (perindoprilat) with the effect of placebo (0.9% NaCl) on endogenously mediated (lower body ...
D, Lyons, S, Roy, S, O'Byrne, C G, Swift
openaire   +2 more sources

Vascular Effects of ACE Inhibition by Perindopril

Drugs, 1990
Hypertension and ageing are associated with decreased arterial compliance, increased thickening of the arterial wall, hypertrophy of arterial smooth muscle cells and an increase in the collagen content of the arterial wall. Increased blood pressure has been implicated as a causative factor in such adaptive vascular alterations, however, other factors ...
J B, Michel, B I, Levy
openaire   +2 more sources

ACE Inhibition in Diabetic Patients

PharmacoEconomics, 1996
Diabetic nephropathy is the inevitable long term complication of prolonged hyperglycaemia for up to 40% of patients with diabetes mellitus. Most patients with renal involvement have a number of comorbid conditions including hypertension, coronary artery disease. peripheral vascular disease and retinopathy.
R A, Rodby, E J, Lewis
openaire   +2 more sources